Research programme: somatropin sustained-release - Critical Pharmaceuticals

Drug Profile

Research programme: somatropin sustained-release - Critical Pharmaceuticals

Alternative Names: CP 016; hGH Depot -Critical Pharmaceuticals; SR somatropin - Critical Pharmaceuticals; sustained-release somatropin - Critical Pharmaceuticals

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Critical Pharmaceuticals
  • Class Growth hormones
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Somatotropin deficiency

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Somatotropin-deficiency in United Kingdom (SC, Injection)
  • 21 Nov 2013 Preclinical development for Somatotropin deficiency is ongoing in the United Kingdom
  • 06 Oct 2008 Preclinical trials in Somatotropin deficiency in United Kingdom (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top